

<b>Protokoltitel</b>	A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Clinical Activity of Durvalumab in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) or with Lenalidomide plus R-CHOP (R2-CHOP) in Subjects With Previously Untreated, High-Risk Diffuse Large B-Cell Lymphoma
<b>Diagnose</b>	Previously untreated, high-risk diffuse-large B-cell lymphoma (DLBCL).
<b>Protokolnummer</b>	MEDI4736-DLBCL-001
<b>Danske centre</b>	RH, Århus & Odense
<b>Formål, design og resume</b>	<p>To explore the clinical activity of durvalumab (MEDI4736) in combination with R-CHOP or R2-CHOP followed by durvalumab consolidation therapy in previously untreated subjects diagnosed with high-risk DLBCL.</p> <p>This Phase 2, two-arm, open-label study is designed to evaluate durvalumab in combination with R-CHOP or in combination with R2-CHOP, followed by durvalumab consolidation therapy in previously untreated subjects with high-risk DLBCL (Figure 1). Induction treatment with R-CHOP will last for a total of up to 6 to 8 treatment cycles, and the total time on study treatment, including durvalumab consolidation, will last up to 12 months.</p> <p>All subjects will be treated with durvalumab combined with R-CHOP during Cycle 1 of induction therapy. Based on their DLBCL cell-of-origin (COO) subtype (Activated B-cell type [ABC] versus non-ABC) as determined by the NanoString 20-gene assay before start of Cycle 2, subjects will be allocated to one of two treatment arms from Cycle 2 onwards:</p>
<b>Hvilke ptt.</b>	Previously untreated, high-risk diffuse-large B-cell lymphoma (DLBCL).
<b>Hvor mange ptt.</b>	120 i alt, på RH: ca. 5
<b>Hvordan</b>	<p>Cyklus 1 er ens i begge arme. Ud fra COO analyse (ABC subtype) behandles patienten i Arm A eller Arm B fra cyklus 2.</p> <p><b>Arm A:</b> Durvalumab 12 months R-CHOP Cycle 2-6 or 8.</p> <p><b>Arm B:</b> Durvalumab 12 months Lenalidomide Cycle 2-6 or 8 R-CHOP Cycle 2-6 or 8.</p> <p><b>FU Arm A+B: Durvalumab I 12 mdr. ialt.</b></p>

<b>Hvor længe</b>	<p>Start: 2017 – slut: ?</p> <p>The study consists of a Screening period (up to 28 days before first dose of study treatment), a treatment period (up to a total of 12 months) and a follow-up period for all subjects for disease progression, or until death, lost to follow-up, or consent withdrawal, for up to 5 years after the last subject is enrolled, whichever occurs first.</p> <p>Subjects receiving lenalidomide will be followed for up to 5 years from the date of enrollment (C1D1) of the last subject, and evaluated for the occurrence of Second Primary Malignancies (SPM).</p>
<b>Særlige dosismodifikationer</b>	<p>Der er mange dosismodifikationer. Se protokol s. 73, 76-102</p>
<b>Særlige in- eller eksklusionskriterier</b>	<p>Se in- &amp; eksklusionskriterier s. 37-42.</p> <p><b>Særlige inklusionskriterier:</b> Subject has documented histologically confirmed CD20+ DLBCL</p> <ul style="list-style-type: none"> <li>• Subject has high-risk disease defined as: Ann Arbor stage 3-4 or Ann Arbor stage 2 with bulky disease (<math>\geq 7.0</math> cm) and IPI <math>\geq 3</math></li> <li>• Subject has bi-dimensionally measurable disease on cross-sectional imaging by CT with at least one (post-biopsy) nodal or extranodal lesion <math>\geq 2.0</math> cm in its longest dimension.</li> <li>• Subject has not received prior anti-lymphoma treatment. 100 mg/day prednisone, or equivalent, for a maximum of 7 days is permitted prior to beginning the Treatment Period, at the discretion of the Investigator.</li> <li>• Subject is considered an appropriate candidate for induction therapy with 6-8 cycles of R-CHOP immuno-chemotherapy.</li> <li>• Performance status 0-2</li> </ul> <p><b>Særlige eksklusionskriterier:</b> Subject has evidence of composite DLBCL and Follicular Lymphoma (FL), or of transformed NHL.</p>
<b>Randomisering hvordan:</b>	Der er to arme i forsøget, hvor arm A er: ptt med non-ABC DLBCL og arm B er: ptt med ABC DLBCL.(Central blodprøve der tages ved screening).
<b>Særlige KAT opgaver</b>	Projektblodprøver, urinstix, graviditetstest- og rådgivning, værdier + vægt & EKG, tastning af data, udlevering af tabl. Lenalidomid.
<b>Andet</b>	
<b>KAT ansvarlig pro. spl.</b>	Navn: Susanne Madsen Tlf. nr. 3545 5112
<b>Forsøgsansvarlig læge</b>	Navn: Peter Brown Tlf. nr. 3545 1128